Use App
AI Agent
Trending
News
Earnings
All
DIA
1.50%
SPY
3.03%
QQQ
4.72%
Trending
CAPR
6.51%
QQQ
4.72%
CRWD
13.33%
SOXL
27.31%
ZS
10.09%
APLD
15.81%
TQQQ
14.51%
MU
12.17%
BTC
4.35%
NVDA
11.67%
Feed
News
Sentiment
Earnings
Fundamentals
Info
Home
Symbol
ALLO
News
Exchange:
NASDAQ
·
Updated 04:44 PM EST
ALLO News
News
all
press releases
Allogene Therapeutics, Inc. (ALLO) Presents at UBS Global Biopharma Conference 2026 Transcript
Allogene Therapeutics, Inc. (ALLO) Presents at UBS Global Biopharma Conference 2026 Transcript...
SeekingAlpha
Share to Feed
Allogene Therapeutics, Inc. (ALLO) Presents at UBS Global Biopharma Conference 2026 Transcript
Allogene Therapeutics, Inc. (ALLO) Presents at UBS Global Biopharma Conference 2026 Transcript...
SeekingAlpha
Share to Feed
More News
CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot
Cellectis received a downgrade after pivoting to cardiovascular diseases therapy from a type of cancer therapy
Stocktwits
Full Article
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Zacks
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.
Zacks
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio
Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio...
Yahoo! Finance: News
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.
Zacks
Allogene Therapeutics Q1 2026 Earnings Call Transcript
read more...
Benzinga
Allogene Therapeutics (ALLO) Projected to Post Quarterly Earnings on Tuesday
Allogene Therapeutics (NASDAQ:ALLO) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-allogene-therapeutics-inc-stock...
MarketBeat
1
2
Advertisement
|
Remove ads.
Home
Watchlist
Trending
News
Explore
Profile